SK bioscience has announced the new domestic launch of MenQuadfi Injection (MenQuadfi, MenACWY-TT), a quadrivalent meningococcal conjugate vaccine, in partnership with the Korean affiliate of global biopharmaceutical company Sanofi.
Developed by Sanofi, MenQuadfi is approved for use in individuals from 6 weeks of age through 55 years and is indicated for the prevention of Invasive Meningococcal Disease (IMD) caused by the major meningococcal serogroups A, C, W, and Y.
Notably, among A, C, W, Y meningococcal vaccines approved in Korea, MenQuadfi is the only product that both includes serogroup A and is approved for use in infants aged 6 weeks to under 24 months. SK bioscience will be responsible for the domestic distribution and supply of the vaccine for infant and pediatric populations.
MenQuadfi is distinguished by its fully liquid formulation, allowing for direct administration without the need for reconstitution. This simplifies vaccine preparation, enhances clinical workflow efficiency, and helps reduce the risk of preparation-related errors in healthcare settings.
The vaccine is administered as a 0.5 mL intramuscular injection, with dosing schedules as follows:
-Infants aged 6 weeks to under 6 months: a total of four doses
-Infants aged 6 months to under 24 months: two doses
- Individuals aged 2 to 55 years: one dose
Meningococcal disease is transmitted through respiratory secretions, such as nasal discharge or saliva, and can be spread even by asymptomatic carriers, underscoring the importance of prevention.
In Korea, the Korea Disease Control and Prevention Agency (KDCA) recommends meningococcal vaccination for individuals at increased risk of infection, including immunocompromised patients, laboratory personnel, new military recruits, university dormitory residents, travelers to or residents of endemic regions, and close contacts during outbreaks.
